SCHEMBL5541669

SCHEMBL5541669

[CH2]c1ccc2nc(C)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
TAS1R3 Q7RTX0 5/20 0.41
TAS1R1 Q7RTX1 5/20 0.41
ELANE P08246 2/20 0.41
HSD17B10 Q99714 1/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543053 0.84 GAA (0.56) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL5541680 0.79 KDM4E (0.63) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL14330030 0.79 GAA (0.59) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL2056293 0.76 PIK3CG (0.61) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL1655934 0.76 POLB (0.55) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL23033213 0.76 ALDH1A1 (0.47) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL353596 0.76 POLB (0.48) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL2490866 0.76 SMN1; SMN2 (0.49) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1
SCHEMBL1655937 0.76 ESR1 (0.58) ALDH1A1POLBSMN1; SMN2NPC1RAB9A
SCHEMBL615340 0.76 SMN1; SMN2 (0.58) ALDH1A1POLBSMN1; SMN2GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885POLB 1637/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.